• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
FinanceInsys Therapeutics

Pharma Billionaire Arrested On Charges of Bribing Doctors to Prescribe Opioid Painkillers

Lucinda Shen
By
Lucinda Shen
Lucinda Shen
Down Arrow Button Icon
Lucinda Shen
By
Lucinda Shen
Lucinda Shen
Down Arrow Button Icon
October 26, 2017, 5:56 PM ET

The same day President Donald Trump declared the opioid crisis a nationwide public health emergency, the federal government said it arrested a wealthy pharmaceutical company executive on charges of bribing doctors to needlessly prescribe his firm’s opioid painkiller.

The Department of Justice arrested Insys Therapeutics founder John Kapoor, 74, in Phoenix, it said Thursday. Kapoor was charged with using bribes and fraud to prop up sales of a pain medication called Subsys, a fentanyl spray typically used to treat cancer patients suffering excruciating pain.

University at Buffalo/ReutersUniversity at Buffalo/Reuters
University at Buffalo/Reuters

Kapoor’s arrest comes nearly a year after former Insys CEO Michael Babich and five other onetime executives were arrested as part of an alleged “nationwide conspiracy.”

The Justice Department claims that Kapoor and other Insys executives offered bribes in the form of kickbacks to doctors who wrote “large numbers of prescriptions” for patients, many of whom did not have cancer. The Department also alleged that the executives defrauded insurers by forming a “reimbursement unit” dedicated to obtaining prior authorization from insurers who were reluctant to pay for the drug.

“These Insys executives allegedly fueled the opioid epidemic by paying doctors to needlessly prescribe an extremely dangerous and addictive form of fentanyl,” Phillip Coyne, special agent in charge for the Office of Inspector General of the U.S. Department of Health and Human Services, said in a press release.

“The allegations of selling a highly addictive opioid cancer pain drug to patients who did not have cancer, make them no better than street-level drug dealer,” added Harold Shaw, a Federal Bureau of Investigation special agent.
Insys did not immediately return Fortune’s request for comment.

Insys’ stock closed down nearly 23% following the news of Kapoor’s arrest, pushing the company’s valuation down to $417 million. It was a stunning retreat, considering the company was valued at over $19 billion as recently as 2015, when concerns about the company’s practices were first raised. (Insys is now also developing its own drug to reverse opioid overdoses.)

Insys’ falloff has cost Kapoor a hefty portion of his own net worth, which is made up in part of company stock. At Insys’ peak, Kapoor’s current stake in the company was worth over $1.9 billion. By Thursday’s close, it was down to $246.7 million. (Kapoor still holds a $1 billion stake in Akorn Pharmaceuticals, a generic drug maker where he also serves as board chairman. Akorn’s stock was down about 1% at Thursday’s close.)
Kapoor is set to make a court appearance in Phoenix at a later date.
About the Author
Lucinda Shen
By Lucinda Shen
See full bioRight Arrow Button Icon

Latest in Finance

Spanish Prime Minister Pedro Sánchez often praises the financial and social benefits that immigrants bring to the country.
EuropeSpain
In a continent cracking down on immigration and berated by Trump’s warnings of ‘civilizational erasure,’ Spain embraces migrants
By Suman Naishadham and The Associated PressDecember 13, 2025
1 hour ago
EconomyAgriculture
More financially distressed farmers are expected to lose their property soon as loan repayments and incomes continue to falter
By Jason MaDecember 13, 2025
2 hours ago
InvestingStock
There have been head fakes before, but this time may be different as the latest stock rotation out of AI is just getting started, analysts say
By Jason MaDecember 13, 2025
5 hours ago
Politicsdavid sacks
Can there be competency without conflict in Washington?
By Alyson ShontellDecember 13, 2025
6 hours ago
Investingspace
SpaceX sets $800 billion valuation, confirms 2026 IPO plans
By Loren Grush, Edward Ludlow and BloombergDecember 13, 2025
7 hours ago
PoliticsAffordable Care Act (ACA)
With just days to go before ACA subsidies expire, Congress is about to wrap up its work with no consensus solution in sight
By Kevin Freking, Lisa Mascaro and The Associated PressDecember 13, 2025
7 hours ago

Most Popular

placeholder alt text
Economy
Tariffs are taxes and they were used to finance the federal government until the 1913 income tax. A top economist breaks it down
By Kent JonesDecember 12, 2025
2 days ago
placeholder alt text
Success
Apple cofounder Ronald Wayne sold his 10% stake for $800 in 1976—today it’d be worth up to $400 billion
By Preston ForeDecember 12, 2025
1 day ago
placeholder alt text
Success
40% of Stanford undergrads receive disability accommodations—but it’s become a college-wide phenomenon as Gen Z try to succeed in the current climate
By Preston ForeDecember 12, 2025
1 day ago
placeholder alt text
Economy
The Fed just ‘Trump-proofed’ itself with a unanimous move to preempt a potential leadership shake-up
By Jason MaDecember 12, 2025
1 day ago
placeholder alt text
Economy
For the first time since Trump’s tariff rollout, import tax revenue has fallen, threatening his lofty plans to slash the $38 trillion national debt
By Sasha RogelbergDecember 12, 2025
1 day ago
placeholder alt text
Success
Apple CEO Tim Cook out-earns the average American’s salary in just 7 hours—to put that into context, he could buy a new $439,000 home in just 2 days
By Emma BurleighDecember 12, 2025
1 day ago
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • Future 50
  • World’s Most Admired Companies
  • See All Rankings
Sections
  • Finance
  • Leadership
  • Success
  • Tech
  • Asia
  • Europe
  • Environment
  • Fortune Crypto
  • Health
  • Retail
  • Lifestyle
  • Politics
  • Newsletters
  • Magazine
  • Features
  • Commentary
  • Mpw
  • CEO Initiative
  • Conferences
  • Personal Finance
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
About Us
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Fortune
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map

© 2025 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.